In this study, we hypothesized that T1 and T3 induced diametrically opposed responses in HCF by differentially activating PDGFRα. To test this hypothesis, PDGFRα was permanently knocked down in HCF-P. These cells were grown either on plates or in our 3D cell-culture model, stimulated in response to T1 or T3, and examined for SMA mRNA expression and protein localization, as well as cell migration. Our data showed that in HCF, T1 significantly stimulated SMA mRNA expression, while T3 had little, if any, effect compared with control (
Figs. 2A), which is in agreement with our previous papers
14,23; however, in HCF-P, both T1 and T3 significantly increased mRNA SMA expression to ∼3 times that of control HCF-P (
Fig. 2A). These results were confirmed by immunofluorescence results (
Figs. 3,
4).
To determine if the difference in T1 and T3's effect on SMA levels was due to the stimulation of PDGF isoforms, we examined the expression of all four PDGF isoforms (A, B, C, and D) in both cell types (
Fig. 5). Interestingly, PDGFC (
Fig. 5C), which has been shown to play an important role in the regulation of fibrosis in different organs,
24,25 notably increased in both HCF and HCF-P upon T1 stimulation. However, no significant difference was apparent with any of the PDGFs upon T3 stimulation when compared to controls for both cell types. Therefore, since PDGFC has been found to regulate fibrosis in various organs,
24,25 T1 may be involved in fibrosis through PDGFC in HCF. Platelet-derived growth factor C also has been shown to activate both PDGFRα and PDGFRαβ,
26 which may explain the residual increase in PDGFC expression in HCF-P. Therefore, our results suggest that in normal HCF, T1's high SMA expression may be through its high PDGFC stimulation, while T3 fails to stimulate PDGFC, thus leading to low SMA expression. However, this fails to explain T3's role in stimulating SMA in HCF-P, which leads us to believe that T3 may be acting through a different mechanism. Further studies are required to understand these relationships; however, we feel these results are quite exciting, in that they are the first data we have obtained that may begin to explain the disparate effects of T1 and T3.
Finally, to look at the functional differences between the two cell types, we looked at construct thickness and cell migration. In previous papers, we have used the thickness of the construct as a measure of the amount of ECM produced and showed that our 3D cell culture model produced a matrix that had a similar structure to the human stroma and contained Collagen type I and V.
23 Measuring the thickness of the constructs in this paper, we found that both T1- and T3-treated cells produced a thicker construct than their untreated control (
Fig. 2B). This may be due to the effects of TGFB's mitogenic properties.
1 The human corneal fibroblast-P constructs, in contrast, were significantly thinner than HCF constructs (
Fig. 2B) and also had a slower migration rate than HCF (
Fig. 5B). We believe this might be due to the fact that PDGFRα is strongly associated with the proliferation and migration of cells.
27,28 Interestingly, neither T1 nor T3 had an effect on HCF-P migration or construct thickness. According to the literature,
28 both PDGFRα and PDGFRβ stimulate fibroblast migration; however, it appears that PDGFRβ does not compensate for the loss of PDGFRα in our model. These results are consistent with our biochemical results that indicated that PDGFRα played a major role in determining T3's mechanism of action in stimulating SMA (
Figs. 2,
3).
To summarize, in this present study we have captured the difference in function of T1 and T3 using our 3D cell culture model. We also showed that the presence or absence of PDGFRα affects T3's ability to stimulate SMA. We believe understanding this relationship between PDGFRα and T3 may be the first step toward developing T3 as an antiscarring therapy for the cornea.